News / Events

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

Jefferies Cell & Genetic Medicine Summit

Sep 27, 2023 • 9:30am EDT

Cantor Global Healthcare Conference

Sep 26, 2023 • 2:10pm EDT